Israel · Delayed Price · Currency is ILS · Price in ILA Bonus BioGroup Statistics
Total Valuation
Bonus BioGroup has a market cap or net worth of ILS 241.80 million. The enterprise value is 249.54 million.
| Market Cap | 241.80M |
| Enterprise Value | 249.54M |
Important Dates
The last earnings date was Friday, August 28, 2026.
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Bonus BioGroup has 1.17 billion shares outstanding.
| Current Share Class | 1.17B |
| Shares Outstanding | 1.17B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 45.36% |
| Owned by Institutions (%) | 0.60% |
| Float | 638.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -28.51 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.10
| Current Ratio | 0.10 |
| Quick Ratio | 0.10 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.54 |
| Interest Coverage | -32.80 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -91.67% |
| Return on Invested Capital (ROIC) | -378.47% |
| Return on Capital Employed (ROCE) | 1,071.96% |
| Weighted Average Cost of Capital (WACC) | 9.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -568,214 |
| Employee Count | 42 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.07% in the last 52 weeks. The beta is 0.89, so Bonus BioGroup's price volatility has been lower than the market average.
| Beta (5Y) | 0.89 |
| 52-Week Price Change | -18.07% |
| 50-Day Moving Average | 26.60 |
| 200-Day Moving Average | 34.77 |
| Relative Strength Index (RSI) | 38.12 |
| Average Volume (20 Days) | 2,015,346 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -23.09M |
| Pretax Income | -23.87M |
| Net Income | -23.87M |
| EBITDA | -21.56M |
| EBIT | -23.09M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 439,000 in cash and 8.18 million in debt, with a net cash position of -7.74 million or -0.01 per share.
| Cash & Cash Equivalents | 439,000 |
| Total Debt | 8.18M |
| Net Cash | -7.74M |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -8.48M |
| Book Value Per Share | n/a |
| Working Capital | -14.60M |
Cash Flow
In the last 12 months, operating cash flow was -15.11 million and capital expenditures -38,000, giving a free cash flow of -15.15 million.
| Operating Cash Flow | -15.11M |
| Capital Expenditures | -38,000 |
| Depreciation & Amortization | 1.53M |
| Net Borrowing | -1.56M |
| Free Cash Flow | -15.15M |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Bonus BioGroup does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -9.87% |
| FCF Yield | -6.26% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |